SIETES :: 93061 citas

Resultados de la búsqueda por USO COMPASIVO REFINAR BÚSQUEDA

1.

Addis A, Ganazzani A, Trotta MP, Magrini N, for the Italian Medicines Agency Scientific Committee and COVID-19 Crisis Unit. Promoting better clinical trials and drug information as public health interventions for the COVID-19 emergency in Italy. Ann Intern Med 2020:16 de junio. [Ref.ID 103673]

2.

Anónimo. Coronavirus (COVID-19) Update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. U.S. Food and Drug Administration 2020:1. [Ref.ID 103663]

3.

Rome BN, Avorn J. Drug evaluation during the covid-19 pandemic. N Engl J Med 2020;382:11 de junio. [Ref.ID 103661]

4.

Sakoulas G, El Sahly H, Ellison III RT. Chloroquine and hydroxychloroquine: old drugs in a new COVID-19 world. Journal Watch 2020:1. [Ref.ID 103608]

5.

Rejón R. Sanidad incorpora dos nuevos medicamentos para aplicar como último recurso en pacientes graves de COVID-19 . eldiario.es 2020:18 de abril. [Ref.ID 103588]

6.

Mershon E. STAT Plus: It’s not over: After defeat on ‘right to try,’ GOP vows to renew push. STAT Daily Recap 2018:2. [Ref.ID 102468]

7.

Harrington M, Sigal EV. Opinion: ‘Right-to-try’ law threatens patient safety and rational drug development. STAT Daily Recap 2018:6. [Ref.ID 102467]

8.

Montanaro N, Melis M, Proni S, Chiabrando G, Motola D. Six-year activity on approval of compassionate use of medicines by the Ethics Committee of the University Hospital of Bologna (Italy): time to update rules and recommendations. Eur J Clin Pharmacol 2017;73:479-85. [Ref.ID 101975]

9.

Martín-González A, Abajo del Álamo C, Catalá Pindado MA, Godoy Díez M. Calidad de la prescripción para indicaciones no autorizadas en ficha técnica (off-label) en la enfermedad oncológica avanzada. Med Clin (Barc) 2015;145:178-9. [Ref.ID 99477]

10.

Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, Garrido MM, Reid MC, Berlin DA, Adelson KB, Neugut AI, Maciejewski PK. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncology 2015;1:778-84. [Ref.ID 99274]

11.

Anónimo. Dépendances (drogues, tabac, alcool). Prescrire 2015;35:37. [Ref.ID 98905]

12.

Gupta-Wright A, Lavers J, Irvine S. Concerns about the off-licence use of amiodarone for Ebola. BMJ 2015;350:h272. [Ref.ID 98715]

13.

Turone F. Doctors trial amiodarone for Ebola in Sierra Leone. BMJ 2014;349:g7198. [Ref.ID 98441]

14.

Danés I, Alerany C, Ferrer A, Vallano A. Utilización hospitalaria de medicamentos en condiciones diferentes a las aprobadas en la ficha técnica. Med Clin (Barc) 2014;143:327-8. [Ref.ID 98116]

15.

Bauer MS, Lee A, Li M, Bajor L, Rasmusson A, Kazis LE. Off-label use of second generation antipsychotics for post-traumatic stress disorder in the Department of Veterans Affairs: time trends and sociodemographic, comorbidity, and regional correlates. Pharmacoepidemiol Drug Saf 2014;23:77-86. [Ref.ID 97002]

16.

Meyerhoff A, Lietman P. Losing the opportunity to study influenza drugs. JAMA 2010;303:878-9. [Ref.ID 87980]

17.

Montero D, Vargas E, de la Cruz C, de Andrés-Trelles F. Nuevo real decreto de acceso a medicamentos en situaciones especiales. Med Clin (Barc) 2009;133:427-32. [Ref.ID 86851]

18.

Avendaño C. Uso compasivo de medicamentos: un cambio necesario en España. Med Clin (Barc) 2009;133:425-6. [Ref.ID 86850]

19.

García Sánchez R, Durán García E, Esteva Jiménez L, Moreno Díaz R, Sanjurjo Sáez M. Estudio de utilización de inmunoglobulinas intravenosas en un hospital general universitario. Aten Farmaceutica 2009;11:143-50. [Ref.ID 86349]

20.

Valerio M. Las razones del batacazo de Yondelis en EEUU. El Mundo 2009:16 julio. [Ref.ID 86263]